|
Volumn 33, Issue 26, 2015, Pages 2835-2836
|
Prognostic significance of diffuse large B-cell lymphoma cell of origin: Seeing the forest and the trees
|
Author keywords
[No Author keywords available]
|
Indexed keywords
ANTINEOPLASTIC AGENT;
CYCLOPHOSPHAMIDE;
DNA;
DOXORUBICIN;
HISTONE DEACETYLASE INHIBITOR;
IMMUNOGLOBULIN ENHANCER BINDING PROTEIN;
MYC PROTEIN;
PREDNISONE;
PROTEIN BCL 2;
RITUXIMAB;
RNA;
VINCRISTINE;
B CELL LYMPHOMA;
B LYMPHOCYTE ACTIVATION;
CANCER CHEMOTHERAPY;
CANCER COMBINATION CHEMOTHERAPY;
CANCER PATIENT;
CANCER PROGNOSIS;
DNA SEQUENCE;
DRUG EFFICACY;
DRUG SAFETY;
EDITORIAL;
GENE EXPRESSION PROFILING;
HUMAN;
IMMUNOHISTOCHEMISTRY;
INTERNATIONAL PROGNOSTIC INDEX;
LARGE CELL LYMPHOMA;
NONHODGKIN LYMPHOMA;
PATIENT SELECTION;
PRIORITY JOURNAL;
PROGRESSION FREE SURVIVAL;
PROTEIN EXPRESSION;
RISK FACTOR;
RNA SEQUENCE;
SIGNAL TRANSDUCTION;
TISSUE SECTION;
TREATMENT OUTCOME;
FEMALE;
MALE;
PATHOLOGY;
FEMALE;
HUMANS;
LYMPHOMA, LARGE B-CELL, DIFFUSE;
MALE;
|
EID: 84953345088
PISSN: 0732183X
EISSN: 15277755
Source Type: Journal
DOI: 10.1200/JCO.2015.61.9288 Document Type: Editorial |
Times cited : (24)
|
References (7)
|